15P HRD status and mutation concordance using ascites-derived cfDNA in high-grade serous ovarian cancer (HGSC): Impact of sample type, cytology and treatment setting
Homologous recombination deficiency (HRD) and genomic alterations are key biomarkers in HGSC. However, approximately 10% of cases yield non-informative HRD results. DNA extracted from ascites, both supernatant and cell pellet, may provide an alternative source to reduce these inconclusive outcomes.
Authors
- G. Tachon
- O. Le Saux
- P. Meeus
- D. Ferraioli
- G. Marcel
- L. Rossi
- A. Buisson
- L. Mbengue
- B. Hanvic
- N. Chopin
- N. Schindelholz
- I.L. Ray-Coquard
Institutions
- Centre Léon Bérard (FR)
- Centre de Recherche en Cancérologie de Lyon (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.108040
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00